Context: Carbohydrate restriction benefits metabolic health in patients with type 2 diabetes (T2D), possibly through changes in hepatic metabolism. Objective: To test the hypothesis that the ketogenic diet (KD) would decrease de novo lipogenesis (DNL) and liver fat, which would be associated with restored beta-cell function. Methods: Participants were 57 adults with mild T2D. A hyperglycemic clamp was used to assess acute C-peptide response (ACP), and magnetic resonance imaging to assess hepatic fat fraction, at baseline and after 12 weeks of either a eucaloric KD (∼9% energy from carbohydrate, 65% energy from fat) or a eucaloric low-fat diet (LFD) (∼55% energy from carbohydrate, 20% energy from fat). Results: The KD led to decreases in pyruvate (−23%, P < .001) and palmitoleic acid, a marker of DNL (−32%, P < .01). Participants on the KD had higher fasting glucagon (25%, P < .05) and lower liver fat (28%, P < .05) at week 12 than those on the LFD. In all combined, the change in liver fat was positively associated with the change in pyruvate (r = 0.45, P = .05), and inversely associated with changes in glucagon (r = −0.34, P < .05), the glucagon to C-peptide ratio (r = −0.44, P < .01), and ACP (r = −0.34, P < .05). The change in ACP was inversely associated with the change in pyruvate in the KD group (r = −0.5, P < .05), but not in the LFD group. Conclusion: A shift in hepatic metabolism to favor fat oxidation over DNL may underlie the beneficial effects of carbohydrate restriction on hepatic steatosis and glucose-induced insulin secretion.
Urinary oxalate is mostly derived from the absorption of ingested oxalate and endogenous synthesis. The breakdown of vitamin C may also contribute small amounts to the urinary oxalate pool. The amount of oxalate absorbed is influenced by the oxalate content of the diet, the concentrations of divalent cations in the gut, the presence of oxalate‐degrading organisms, transport characteristics of the intestinal epithelium, and other factors associated with the intestinal environment. Knowledge of pathways associated with endogenous oxalate synthesis is limited. Urinary oxalate excretion can be modified using strategies that limit dietary oxalate absorption and the ingestion of oxalogenic substrates such as hydroxyproline.
7 April 2025 in Journal of the American Society of Nephrology
Key Points: Primary hyperoxalurias are genetic diseases defined by elevated hepatic oxalate production and higher incidence of kidney stones. Lactate dehydrogenase A catalyzes the final and committed step in hepatic oxalate synthesis and represents a potential therapeutic target for primary hyperoxalurias. CHK-336 is a liver-targeted, small-molecule lactate dehydrogenase A inhibitor with potential to treat diseases associated with elevated oxalate production. Background: Primary hyperoxalurias (PH) 1–3 are genetic diseases defined by elevated hepatic oxalate production and higher incidence of calcium oxalate kidney stones and potentially kidney failure. There are two approved agents available for PH1, and there are no approved therapies for PH2 or PH3. Lactate dehydrogenase A catalyzes the final step in hepatic oxalate synthesis and represents a potential therapeutic target for PH and other forms of hyperoxaluria associated with increased oxalate production. Methods: Potent and selective lactate dehydrogenase (LDH) inhibitors with liver-targeted tissue distribution were identified and characterized in enzymatic, cellular, and in vivo models. Results: We identified CHK-336, a novel oral small-molecule that demonstrates potent and selective inhibition of the human LDH enzyme and its activity in hepatocyte assays across multiple species, including hepatocytes isolated from PH1 mice. CHK-336 demonstrated a favorable liver distribution profile in mice, rats, and monkeys that was dependent on hepatic uptake by organic anion-transporting polypeptide transporters and target-mediated drug binding. In a rat pharmacodynamic model, CHK-336 inhibited conversion of 13 C 2 -glycolate to 13 C 2 -oxalate in a dose-dependent manner. In a PH1 mouse model, once-daily oral dosing of CHK-336 produced robust and dose-dependent reductions in urinary oxalate to the normal range. Seven days of treatment with CHK-336 also resulted in a significant reduction in urinary oxalate in a PH2 mouse model. Conclusions: In conclusion, CHK-336 is a potent, liver-targeted, small-molecule LDH inhibitor that suppressed urinary oxalate production in a rat pharmacodynamic model and mouse models of PH1 and PH2.